Wavelength-Pharmaceuticals-Insert
X

Find Novel Psychiatry/Psychology Drugs in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KUR-101

            Therapeutic Area: Psychiatry/Psychology Product Name: KUR-101

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: ATAI Life Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition July 09, 2020

            Details:

            Kures' flagship product, KUR-101, is a derivative of mitragynine, the major active alkaloid of the kratom plant. KUR-101 will join ATAI's pipeline of ground-breaking mental health interventions such as arketamine and psilocybin.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Duloxetine Hydrochloride

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 08, 2020

            Details:

            Duloxetine hydrochloride is a serotonin and norepinephrine reuptake inhibitor (SNRI) and the delayed-release capsules, for oral use, were first approved in the U.S. in 2004.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cybin Corp

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 07, 2020

            Details:

            Cybin has entered into a feasibility agreement with IntelGenx Corp for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin, subject to receipt of all necessary regulatory approvals.

            NeuroPharma

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Mydecine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition June 10, 2020

            Details:

            Mydecine and NeuroPharm will combine to focus on an integrated health and wellness research strategy and the development of products underpinned by therapies to assist veterans with mental health issues.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Non-opioid drug

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: March of Dimes

            Deal Size: $1.1 million Upfront Cash: Undisclosed

            Deal Type: Funding June 04, 2020

            Details:

            The current Innovative Challenge Grant allows Katana Pharmaceutical to develop a novel non-opioid treatment for neonatal abstinence syndrome (NAS).

            Delos Psyche Research Group

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lysergide

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: New Wave Holdings Corp

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding June 04, 2020

            Details:

            Funding will support the Delos Psyche Research Group in its study designed to determine the impact of ingesting small amounts of hallucinogenic or psychedelic substances such as lysergic acid diethylamide for medicinal or therapeutic purposes.

            University Hospital Basel

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Methylenedioxymethamphetamine

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Mind Medicine

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration May 27, 2020

            Details:

            MindMed has committed to fund future R&D of new psychedelic therapies being pursued by the Liechti Lab with the intention to create next-gen psychedelic inspired medicines that incorporate MDMA as a component of these therapies.

            National Institute on Drug Abuse

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: CaaMTech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 07, 2020

            Details:

            The Designer Drug Research Unit at the National Institute on Drug Abuse will conduct research on CaaMTech's library of tryptamine-based compounds.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PH94B

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 28, 2020

            Details:

            VistaGen plans to submit its proposed protocol for a Phase 2 study of PH94B for treatment of adjustment disorder to the U.S. FDA through the FDA's new Coronavirus Treatment Acceleration Program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Psilocybine

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Cleveland Clinic

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 20, 2020

            Details:

            The MOU singed between the companies include, production of psilocybin and like molecules used in combination with psychotherapy for the treatment of depression and addiction, and two other molecule.

            PharmaCompass